Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514324 | 0.85 | RXFP1 (0.53) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL10192912 | 0.81 | XDH (0.46) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL29217462 | 0.81 | XDH (0.48) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL30988744 | 0.81 | XDH (0.48) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL16030973 | 0.81 | XDH (0.48) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL2735992 | 0.81 | XDH (0.44) | XDHKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2760136 | 0.79 | XDH (0.51) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL8985887 | 0.79 | POLB (0.47) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL18824232 | 0.79 | POLB (0.48) | XDHKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL29217465 | 0.78 | XDH (0.48) | XDHKDM4EALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-7901894-B2 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-02-03 | — | — | US | disclosed |
| EP-1147214-B1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | UNIV NEW YORK STATE RES FOUND (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| US-7427608-B2 | Protection against and treatment of hearing loss | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427608-B2 | Protection against and treatment of hearing loss | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | OAKTREE FUND ADMINISTRATION, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | OAKTREE FUND ADMINISTRATION, LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2008002674-A2 | BICYCLIC COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | PTPN5, PTPN2, PTPN4 | XDH 3574/4885KDM4E 1123/4885ALDH1A1 4474/4885 |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | PTK2B, GRK2, FRK | XDH 3391/4885KDM4E 2304/4885ALDH1A1 4443/4885 |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | MAP3K20, MAP3K6, MAP3K2 | XDH 3206/4885KDM4E 2169/4885ALDH1A1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.